IRESSA 250 (Iressa 250 mg)
Generic Name: gefitinib
Pill imprint IRESSA 250 has been identified as Iressa 250 mg.
Iressa is used in the treatment of non-small cell lung cancer and belongs to the drug class EGFR inhibitors. There is positive evidence of human fetal risk during pregnancy. Iressa 250 mg is not subject to the Controlled Substances Act.
See also related documents.
Images for IRESSA 250 (Iressa 250 mg)
- Generic Name:
- gefitinib
- Imprint:
-
IRESSA 250
- Strength:
- 250 mg
- Color:
- Brown
- Size:
- 11.00 mm
- Shape:
- Round
- Availability:
- Prescription only
- Drug Class:
- EGFR inhibitors
- Pregnancy Category:
- D - Positive evidence of risk
- CSA Schedule:
- N - Not a controlled drug
- Manufacturer:
- AstraZeneca Pharmaceuticals
- National Drug Code (NDC):
- 00310-0482
- Inactive Ingredients:
- lactose monohydrate
microcrystalline cellulose
croscarmellose sodium
povidone
sodium lauryl sulfate
magnesium stearate
hypromellose
polyethylene glycol 300
titanium dioxide
ferric oxide red
ferric oxide yellow
More resources
Iressa is associated with the treatment of:
Search by Imprint, Shape or Color
Note: All fields are optional. Use the pill finder to identify medications by visual appearance or name. All Rx and OTC drugs in the US are required by the FDA to have an imprint. If your pill has no imprint it could be a vitamin, diet/herbal/energy pill, illicit or foreign drug. More about imprint codes...

